Literature DB >> 30414720

Prevalence, course and psychosis-predictive value of negative symptoms in 22q11.2 deletion syndrome.

Maude Schneider1, Marco Armando2, Frauke Schultze-Lutter3, Maria Pontillo4, Stefano Vicari4, Martin Debbané5, Stephan Eliez6.   

Abstract

BACKGROUND: The 22q11.2 deletion syndrome (22q11DS) is one of the highest known risk factors for schizophrenia and recent findings have highlighted the clinical relevance of ultra-high risk (UHR) criteria in this population. However, studies in other at-risk populations have shown that the presence of negative symptoms (NS) is also of clinical relevance in predicting transition to psychosis. The present study examined in detail the presence and course of NS in 22q11DS, as well as their value in predicting transition to psychosis.
METHODS: A total of 111 participants aged between 8 and 33 years were assessed with the Structured Interview for Psychosis-Risk Syndromes (SIPS). A follow-up assessment was available for 89 individuals.
RESULTS: Core NS of at least moderate severity were present in 50.5% of the sample and were more severe in individuals meeting UHR criteria. They predominantly remained stable over time and their emergence between baseline and follow-up assessment was associated with significant functional decline. Some NS were significant predictors of conversion to psychosis and the emergence/persistence of psychosis risk.
CONCLUSIONS: Altogether, these findings highlight that NS are core manifestations of psychosis in individuals with 22q11DS that strongly impact global functioning. The presence of NS should be a primary target of early therapeutic intervention in this population.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adolescence; Global functioning; Longitudinal; Schizophrenia; Transition

Mesh:

Year:  2018        PMID: 30414720     DOI: 10.1016/j.schres.2018.10.014

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  5 in total

1.  Contribution of schizophrenia polygenic burden to longitudinal phenotypic variance in 22q11.2 deletion syndrome.

Authors:  Maris Alver; Valentina Mancini; Kristi Läll; Maude Schneider; Luciana Romano; Reedik Mägi; Emmanouil T Dermitzakis; Stephan Eliez; Alexandre Reymond
Journal:  Mol Psychiatry       Date:  2022-06-29       Impact factor: 13.437

2.  Neural and behavioral measures suggest that cognitive and affective functioning interactions mediate risk for psychosis-proneness symptoms in youth with chromosome 22q11.2 deletion syndrome.

Authors:  Samantha R Linton; Abbie M Popa; Steven J Luck; Khalima Bolden; Cameron S Carter; Tara A Niendam; Tony J Simon
Journal:  Am J Med Genet A       Date:  2020-04-22       Impact factor: 2.578

3.  Goal-Directed-Behavior in 22q11.2 Deletion Syndrome: Implication for Social Dysfunctions and the Emergence of Negative Symptoms.

Authors:  Lydia Dubourg; Johanna Maeder; Virginie Pouillard; Stephan Eliez; Maude Schneider
Journal:  Front Psychiatry       Date:  2020-04-01       Impact factor: 4.157

Review 4.  Neurodevelopmental Trajectories and Psychiatric Morbidity: Lessons Learned From the 22q11.2 Deletion Syndrome.

Authors:  Ania M Fiksinski; Maude Schneider; Janneke Zinkstok; Danielle Baribeau; Samuel J R A Chawner; Jacob A S Vorstman
Journal:  Curr Psychiatry Rep       Date:  2021-02-24       Impact factor: 5.285

5.  Inter-rater reliability of subthreshold psychotic symptoms in individuals with 22q11.2 deletion syndrome.

Authors:  Tyler M Moore; Deby Salzer; Doron Gothelf; Carrie E Bearden; Monica E Calkins; Wendy R Kates; Leila Kushan; Robert Sean Gallagher; Dafna Sofrin Frumer; Ronnie Weinberger; Donna M McDonald-McGinn; Raquel E Gur
Journal:  J Neurodev Disord       Date:  2021-06-14       Impact factor: 4.025

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.